Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Independent specialty pharmaceuticals firm Medicis has received FDA approval for its new drug application for Vanos, a class I corticosteroid for the treatment of plaque-type psoriasis.
Subscribe to our email newsletter
Vanos, which is manufactured by Patheon Inc in Canada, is a patented corticosteroid cream formulation for once or twice daily application which embodies the heritage of Lidex (fluocinonide), the sixth most recognized dermatology brand in North America.
The product offers the established safety of fluocinonide with the potency of a class I topical corticosteroid, the latter of which has a market value in the United States of approximately $329 million.
“We are pleased to announce the FDA’s approval of Vanos,” said Jonah Shacknai, chairman and CEO of Medicis. “We believe Vanos, which is patent protected until 2021, enhances our therapeutic product portfolio and will be a significant addition to physicians’ treatment regime.”
Medicis anticipates launching Vanos to dermatologists in the quarter beginning April 2005.